> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review restates GLP-1 trial reductions in cardiovascular events and all-cause mortality
- URL: https://www.coios.me/review-restates-glp-1-trial-reductions-in-cardiovascular/
- Published: 2026-09-15T21:44:04.000Z
- Updated: 2026-09-15T21:44:04.000Z
- Description: A narrative review in a Dutch cardiology journal restates the established trial evidence that GLP-1 receptor agonists reduce major adverse cardiovascular events, all-cause mortality and heart-failure hospitalisation in type 2 diabetes, with SELECT extending the effect to obesity without diabetes.
- Author: Daniel Ryan
- Tags: Healthcare today, Cardiovascular disease, Obesity, diabetes and the GLP-1 drugs, World, #peer-reviewed, #confirms, #item

The review surveys the mechanisms and trial evidence for GLP-1 receptor agonists in cardiometabolic disease, drawing on large cardiovascular-outcome trials in type 2 diabetes and on SELECT in overweight or obesity without diabetes. It reports consistent reductions in major adverse cardiovascular events, all-cause mortality and heart-failure hospitalisations, with part of the SELECT benefit described as independent of weight loss. No new data are presented.

*Why it is interesting: A compact statement of where the GLP-1 cardiovascular evidence stands, though it adds no new estimate.*

Source

[Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 2026-09-14](https://doi.org/10.1007/s12471-026-02073-3?ref=coios.me)

DOI

10.1007/s12471-026-02073-3

Type

Peer-reviewed article

Design

Narrative review of published cardiovascular-outcome trials of GLP-1 receptor agonists

Verdict

Confirms prior evidence

Driver

[Cardiovascular disease](https://www.coios.me/d-cardiovascular/)

Driver

[Obesity, diabetes and the GLP-1 drugs](https://www.coios.me/d-obesity-diabetes/)